Skip Navigation


Annals of Oncology Advance Access originally published online on August 22, 2007
Annals of Oncology 2007 18(10):1646-1651; doi:10.1093/annonc/mdm277
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/10/1646    most recent
mdm277v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Findlay, B.
Right arrow Articles by Shepherd, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Findlay, B.
Right arrow Articles by Shepherd, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast cancer

A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes

B. Findlay1,*, K. Tonkin2, M. Crump3, B. Norris4, M. Trudeau5, M. Blackstein6, M. Burnell7, J. Skillings8, D. Bowman9, D. Walde10, M. Levine11, K. I. Pritchard5, M. J. Palmer12, D. Tu12 and L. Shepherd12

1 Hotel Dieu Hospital, St Catharines
2 Cross Cancer Institute, Edmonton
3 OCI/Princess Margaret Hospital, Toronto
4 BC Cancer Agency–Fraser Valley Centre, Surrey
5 Toronto Sunnybrook Regional Cancer Centre, Toronto
6 Mount Sinai Hospital, Toronto
7 Saint John Regional Hospital, Saint John
8 (Not yet determined)
9 BCCA Vancouver Island Cancer Centre, Vancouver
10 Algoma Regional Cancer Program, Sault Area Hospital, Sault Ste Marie
11 Henderson Hospital, Hamilton
12 National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada

* Correspondence to: Dr B. Findlay, Hotel Dieu Hospital, St Catharines, 155 Ontario Street, St Catharines, Ontario L2R 5K3, Canada. Tel: 905-682-6451; Fax: 905-685-1201; E-mail: brian.findlay{at}hdhsc.org

Background: Dose-dense and dose-intensive regimens have improved the outcome of breast cancer in high-risk women with operable disease.

Patients and methods: Sixty-three premenopausal women with Stage 2, 3 breast cancer and ≥4 positive axillary nodes were treated in three successive cohorts with 70 mg/m2 of epirubicin, 500 mg/m2 of 5-fluorouracil and G-CSF every 14 days for 12 cycles. Cyclophosphamide (C) was given at 700 mg/m2, 900 mg/m2, and 1100 mg/m2 doses. Patients were evaluated for dose-limiting toxicities (DLTs) in the first four cycles, the primary endpoint of the trial.

Results: No DLTs were seen at C 700 mg/m2; at C 900 mg/m2 two of 16 patients experienced febrile neutropenia and poor performance status; at C 1100 mg/m2, 1 of 31 patients experienced poor performance status. Over 6 months, febrile neutropenia, grade 4 thrombocytopenia, grade 3 anemia and severe fatigue were observed. Clinical congestive heart failure occurred in three patients over 4 years.

Conclusion: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity. Cyclophosphamide could be increased to more than twice the standard dose at the cost of more anemia and fatigue.

Key words: breast cancer, adjuvant chemotherapy, premenopausal

Received for publication October 20, 2006. Revision received March 15, 2007. Accepted for publication April 30, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.